<sec disp-level="2" id="s02"><title>Introduction</title><p>Although cytokines play critical roles in host defense and immune homeostasis, they can also be key mediators of inflammatory pathology. This paradoxical aspect of cytokine biology is perhaps best exemplified in the dichotomous functions of type I IFN in health and disease. The type I IFN family is a multigene cytokine family that encodes numerous partially homologous IFN-&#x003b1; subtypes, a single IFN-&#x003b2;, and several other poorly defined single genes products (<xref rid="bib97" ref-type="bibr">Pestka et al., 2004</xref>). All type I IFN share a ubiquitously expressed heterodimeric receptor composed of the subunits IFNAR1 and IFNAR2, which signal through STAT1 and STAT2 to activate a broad family of IFN-stimulated genes (ISGs; <xref rid="bib97" ref-type="bibr">Pestka et al., 2004</xref>; <xref rid="bib60" ref-type="bibr">Ivashkiv and Donlin, 2014</xref>). Dominant IFNAR1 expression has been shown to favor IFN-&#x003b2; ligation and activation of the protein kinase B (also known as Akt) pathway over the classical JAK&#x02013;STAT pathway (<xref rid="bib35" ref-type="bibr">de Weerd et al., 2013</xref>). ISGs either stimulate or inhibit immune function and in so doing have host-protective or detrimental effects. Thus, although type I IFN is well known for its antiviral activity and stimulation of effector T cell responses (<xref rid="bib124" ref-type="bibr">Yan and Chen, 2012</xref>; <xref rid="bib25" ref-type="bibr">Crouse et al., 2015</xref>), it has also been implicated in autoimmune diseases (<xref rid="bib58" ref-type="bibr">Hall and Rosen, 2010</xref>) and exacerbation of bacterial and even certain viral infections (<xref rid="bib29" ref-type="bibr">Decker et al., 2005</xref>; <xref rid="bib117" ref-type="bibr">Trinchieri, 2010</xref>; <xref rid="bib28" ref-type="bibr">Davidson et al., 2015</xref>; <xref rid="bib85" ref-type="bibr">McNab et al., 2015</xref>).</p><p>The host beneficial protective effects of type I IFN have been most thoroughly studied in viral infections where these cytokines stimulate the production of innate antiviral proteins and promote effector CD8<sup>+</sup> T cell responses (<xref rid="bib25" ref-type="bibr">Crouse et al., 2015</xref>). The deleterious effects of type I IFN seen in autoimmune diseases such as lupus or in the genetically based interferonopathies appear to stem largely from dysregulated cytokine synthesis (<xref rid="bib5" ref-type="bibr">Banchereau and Pascual, 2006</xref>; <xref rid="bib26" ref-type="bibr">Crow, 2015</xref>). Nevertheless, cytokine overproduction does not provide a unifying explanation for the deleterious activity of type I IFN in infections with bacteria such as <italic>Listeria monocytogenes</italic>, <italic>Brucella abortus</italic>, and <italic>Staphylococcus aureus</italic> (<xref rid="bib85" ref-type="bibr">McNab et al., 2015</xref>; <xref rid="bib114" ref-type="bibr">Stifter and Feng, 2015</xref>).</p><p>The present review focuses on the role of type I IFN in the immune response to <italic>Mycobacterium tuberculosis.</italic> This topic has received great attention (<xref rid="bib92" ref-type="bibr">O&#x02019;Garra et al., 2013</xref>; <xref rid="bib78" ref-type="bibr">Mayer-Barber and Sher, 2015</xref>; <xref rid="bib40" ref-type="bibr">Donovan et al., 2017</xref>; <xref rid="bib105" ref-type="bibr">Sabir et al., 2017</xref>) both because of the global public health importance of this pathogen and the now numerous studies linking type I IFN expression with tuberculosis. However, recent data suggest that even in the prominent example of tuberculosis, the &#x0201c;foe&#x0201d;-like properties of type I IFN are not ironclad and the same cytokines can display &#x0201c;friendly&#x0201d; protective functions under different settings of host&#x02013;pathogen encounter. Deciphering the mechanisms underlying these opposing activities of type I IFN in tuberculosis should contribute enormously to our understanding of the pathogenesis of this important disease while providing new insights into how this major cytokine pathway can be manipulated to ensure beneficial rather than deleterious outcomes for the host.</p></sec><sec disp-level="2" id="s03"><title>Role of cytokines in the immune response in tuberculosis</title><p>Despite being one of the oldest diseases, tuberculosis remains a devastating public health problem. Worldwide, 6.3 million new cases and 1.67 million deaths (of which 0.37 million were in HIV-positive coinfected individuals) were reported in 2016 alone (<xref rid="bib123" ref-type="bibr">World Health Organization, 2017</xref>). Although most individuals exposed to <italic>M. tuberculosis</italic> generate an effective immune response and remain clinically asymptomatic (latent infection), &#x0223c;10% of the infected individuals will progress to active disease at some stage of their lifetime, presenting with clinical signs and symptoms of tuberculosis and, in a significant proportion of patients, cultivable <italic>bacilli</italic> in the sputum (<xref rid="bib68" ref-type="bibr">Lawn and Zumla, 2011</xref>; <xref rid="bib92" ref-type="bibr">O&#x02019;Garra et al., 2013</xref>; <xref rid="bib51" ref-type="bibr">Getahun et al., 2015</xref>). Several mechanisms have been described that result in the development of a protective immune response that controls infection (<xref rid="bib45" ref-type="bibr">Flynn and Chan, 2001</xref>; <xref rid="bib90" ref-type="bibr">North and Jung, 2004</xref>; <xref rid="bib20" ref-type="bibr">Cooper, 2009</xref>; <xref rid="bib92" ref-type="bibr">O&#x02019;Garra et al., 2013</xref>); however, the host immune mechanisms underlying progression to active disease remain poorly understood.</p><p>The role of cytokines in host protection against <italic>M. tuberculosis</italic> infection is well established and was first demonstrated in experimental mouse models of infection that established critical roles for IFN-&#x003b3; (<xref rid="bib21" ref-type="bibr">Cooper et al., 1993</xref>; <xref rid="bib46" ref-type="bibr">Flynn et al., 1993</xref>), TNF-&#x003b1; (<xref rid="bib47" ref-type="bibr">Flynn et al., 1995a</xref>), and IL-12 (<xref rid="bib22" ref-type="bibr">Cooper et al., 1995</xref>, <xref rid="bib23" ref-type="bibr">1997</xref>; <xref rid="bib48" ref-type="bibr">Flynn et al., 1995b</xref>) in controlling infection. Importantly, these early discoveries were corroborated by studies of human tuberculosis establishing the requirement of the same cytokines for protection. Patients with rheumatoid arthritis or Crohn&#x02019;s disease who were latently infected with <italic>M. tuberculosis</italic>, when treated with anti&#x02013;TNF-&#x003b1; antibodies or soluble receptor for TNF, showed an increased rate of progression to active tuberculosis (<xref rid="bib65" ref-type="bibr">Keane et al., 2001</xref>), corroborating a critical role for TNF-&#x003b1; in human tuberculosis. Moreover, human Mendelian susceptibility to mycobacterial disease resulting from deficient IL-12 or IFN-&#x003b3; signaling confers high susceptibility to <italic>M. tuberculosis</italic> and other mycobacterial infections (<xref rid="bib89" ref-type="bibr">Newport et al., 1996</xref>; <xref rid="bib2" ref-type="bibr">Altare et al., 1998</xref>; <xref rid="bib30" ref-type="bibr">de Jong et al., 1998</xref>; <xref rid="bib63" ref-type="bibr">Jouanguy et al., 1999</xref>; <xref rid="bib49" ref-type="bibr">Fortin et al., 2007</xref>). Finally, it is well known that HIV-positive individuals with reduced CD4<sup>+</sup> T cells, the main source of IFN-&#x003b3; during <italic>M. tuberculosis</italic> infection, also display increased susceptibility to tuberculosis (<xref rid="bib98" ref-type="bibr">Post et al., 1995</xref>). The mechanisms underlying the role of these cytokines was later described as an IL-12/IFN-&#x003b3; axis in which IL-12, produced early in infection by APCs, promotes the differentiation of CD4<sup>+</sup> T helper 1 (Th1) cells and IFN-&#x003b3; production. IFN-&#x003b3; further activates macrophages to produce TNF-&#x003b1; and other protective cytokines, promoting intracellular killing of the pathogen through the production of reactive oxygen and nitrogen species (<xref rid="bib45" ref-type="bibr">Flynn and Chan, 2001</xref>; <xref rid="bib90" ref-type="bibr">North and Jung, 2004</xref>; <xref rid="bib20" ref-type="bibr">Cooper, 2009</xref>; <xref rid="bib92" ref-type="bibr">O&#x02019;Garra et al., 2013</xref>).</p></sec><sec disp-level="2" id="s04"><title>Type I IFN&#x02013;inducible transcriptional signature in human tuberculosis</title><p>In contrast to the now well-established protective function of IFN-&#x003b3;, the pathogenic role of type I IFN in tuberculosis has only recently been appreciated. The first evidence revealing a role for type I IFN in the pathogenesis of human tuberculosis was provided a few years ago by a transcriptomic study of patients with active disease and latently infected or healthy individuals from the UK and South Africa (<xref rid="bib9" ref-type="bibr">Berry et al., 2010</xref>). Blood transcriptional profiles of patients with active tuberculosis were dominated by a type I IFN-inducible gene signature that correlated with the extent of lung radiographic disease and diminished with successful treatment (<xref rid="bib9" ref-type="bibr">Berry et al., 2010</xref>). Several other studies have since verified these findings in additional patient cohorts from different geographic regions with diverse host genetic and tuberculosis epidemiological backgrounds (<xref rid="bib70" ref-type="bibr">Maertzdorf et al., 2011a</xref>,<xref rid="bib71" ref-type="bibr">b</xref>, <xref rid="bib72" ref-type="bibr">2012</xref>; <xref rid="bib11" ref-type="bibr">Bloom et al., 2012</xref>, <xref rid="bib12" ref-type="bibr">2013</xref>; <xref rid="bib94" ref-type="bibr">Ottenhoff et al., 2012</xref>; <xref rid="bib18" ref-type="bibr">Cliff et al., 2013</xref>; <xref rid="bib102" ref-type="bibr">Roe et al., 2016</xref>; <xref rid="bib126" ref-type="bibr">Zak et al., 2016</xref>; <xref rid="bib107" ref-type="bibr">Sambarey et al., 2017b</xref>; <xref rid="bib111" ref-type="bibr">Singhania et al., 2017</xref>; <xref rid="bib42" ref-type="bibr">Esmail et al., 2018</xref>; <xref ref-type="table" rid="tbl1">Table 1</xref>). In addition, integration and meta-analysis of diverse human tuberculosis datasets confirmed the reproducibility of the type I IFN&#x02013;inducible blood transcriptional signature in human tuberculosis (<xref rid="bib62" ref-type="bibr">Joosten et al., 2013</xref>; <xref rid="bib10" ref-type="bibr">Blankley et al., 2016</xref>; <xref rid="bib106" ref-type="bibr">Sambarey et al., 2017a</xref>; <xref rid="bib111" ref-type="bibr">Singhania et al., 2017</xref>; <xref ref-type="table" rid="tbl1">Table 1</xref>). Analysis of purified cells from the blood of patients with active disease showed overexpression of IFN-inducible genes in neutrophils and monocytes, but not in CD4<sup>+</sup> or CD8<sup>+</sup> T cells (<xref rid="bib9" ref-type="bibr">Berry et al., 2010</xref>; <xref rid="bib12" ref-type="bibr">Bloom et al., 2013</xref>), suggesting that overactivation of monocytes and neutrophils by type I IFN during infection may contribute to disease pathogenesis.</p><table-wrap id="tbl1" orientation="portrait" position="float"><?Table Large?><label>Table 1.</label><caption><title>Type I IFN&#x02013;inducible blood transcriptional signature in human tuberculosis</title></caption><table frame="hsides" rules="groups"><col width="10%" span="1"/><col width="10%" span="1"/><col width="8%" span="1"/><col width="15%" span="1"/><col width="6%" span="1"/><col width="11%" span="1"/><col width="7%" span="1"/><col width="8%" span="1"/><col width="8%" span="1"/><col width="9%" span="1"/><col width="8%" span="1"/><thead><tr><th rowspan="2" align="left" scope="col" colspan="1">Original study</th><th rowspan="2" align="left" scope="col" colspan="1">Geographic location</th><th rowspan="2" align="left" scope="col" colspan="1">Sample type</th><th rowspan="2" align="left" scope="col" colspan="1">Cohort size</th><th colspan="3" align="left" scope="colgroup" rowspan="1">&#x025cf; Type I IFN signature shown in original study</th><th colspan="4" align="left" scope="colgroup" rowspan="1">o Type I IFN signature reported in subsequent analysis</th></tr><tr><th colspan="1" align="left" scope="colgroup" rowspan="1">Active disease</th><th align="left" scope="col" rowspan="1" colspan="1">Correlated radiographical disease</th><th align="left" scope="col" rowspan="1" colspan="1">Treatment response</th><th align="left" scope="col" rowspan="1" colspan="1"><xref rid="bib62" ref-type="bibr">Joosten et al., 2013</xref></th><th align="left" scope="col" rowspan="1" colspan="1"><xref rid="bib10" ref-type="bibr">Blankley et al., 2016</xref></th><th align="left" scope="col" rowspan="1" colspan="1"><xref rid="bib106" ref-type="bibr">Sambarey et al., 2017a</xref></th><th align="left" scope="col" rowspan="1" colspan="1"><xref rid="bib111" ref-type="bibr">Singhania et al., 2017</xref></th></tr></thead><tbody><tr><td align="left" scope="row" rowspan="1" colspan="1"><xref rid="bib61" ref-type="bibr">Jacobsen et al., 2007</xref></td><td align="left" rowspan="1" colspan="1">Germany</td><td align="left" rowspan="1" colspan="1">PBMCs</td><td align="left" rowspan="1" colspan="1">Active TB (<italic>n</italic> = 9); LTBI (<italic>n</italic> = 9)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>o</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><xref rid="bib86" ref-type="bibr">Mistry et al., 2007</xref></td><td align="left" rowspan="1" colspan="1">South Africa</td><td align="left" rowspan="1" colspan="1">Whole blood</td><td align="left" rowspan="1" colspan="1">Active, recurrent, or cured TB; LTBI (<italic>n</italic> = 10/group)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>o</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td rowspan="2" align="left" scope="row" colspan="1"><xref rid="bib9" ref-type="bibr">Berry et al., 2010</xref><xref ref-type="table-fn" rid="ttbl1n2"><sup>a</sup></xref></td><td align="left" rowspan="1" colspan="1">UK</td><td align="left" rowspan="1" colspan="1">Whole blood (and sorted cells)</td><td align="left" rowspan="1" colspan="1">Active TB (<italic>n</italic> = 21); LTBI (<italic>n</italic> = 21); HCs (<italic>n</italic> = 12)</td><td align="left" rowspan="1" colspan="1"><bold>&#x025cf;</bold></td><td align="left" rowspan="1" colspan="1"><bold>&#x025cf;</bold></td><td align="left" rowspan="1" colspan="1"><bold>&#x025cf;</bold></td><td align="left" rowspan="1" colspan="1"><bold>o</bold></td><td align="left" rowspan="1" colspan="1"><bold>o</bold></td><td align="left" rowspan="1" colspan="1"><bold>o</bold></td><td align="center" rowspan="1" colspan="1"><bold>o</bold></td></tr><tr><td colspan="1" align="left" scope="row" rowspan="1">South Africa</td><td align="left" rowspan="1" colspan="1">Whole blood</td><td align="left" rowspan="1" colspan="1">Active TB (<italic>n</italic> = 20); LTBI (<italic>n</italic> = 31)</td><td align="left" rowspan="1" colspan="1"><bold>&#x025cf;</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>o</bold></td><td align="left" rowspan="1" colspan="1"><bold>o</bold></td><td align="left" rowspan="1" colspan="1"><bold>o</bold></td><td align="center" rowspan="1" colspan="1"><bold>o</bold></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><xref rid="bib70" ref-type="bibr">Maertzdorf et al., 2011a</xref></td><td align="left" rowspan="1" colspan="1">South Africa</td><td align="left" rowspan="1" colspan="1">Whole blood</td><td align="left" rowspan="1" colspan="1">Active TB (<italic>n</italic> = 46); LTBI (<italic>n</italic> = 25); HC (<italic>n</italic> = 37)</td><td align="left" rowspan="1" colspan="1">&#x025cf;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>o</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>o</bold></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><xref rid="bib71" ref-type="bibr">Maertzdorf et al., 2011b</xref></td><td align="left" rowspan="1" colspan="1">The Gambia</td><td align="left" rowspan="1" colspan="1">Whole blood</td><td align="left" rowspan="1" colspan="1">Active TB (<italic>n</italic> = 33); LTBI (<italic>n</italic> = 34); HC (<italic>n</italic> = 9)</td><td align="left" rowspan="1" colspan="1">&#x025cf;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>o</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><xref rid="bib11" ref-type="bibr">Bloom et al., 2012</xref></td><td align="left" rowspan="1" colspan="1">South Africa</td><td align="left" rowspan="1" colspan="1">Whole blood</td><td align="left" rowspan="1" colspan="1">active TB (<italic>n</italic> = 33); LTBI (<italic>n</italic> = 34); HC (<italic>n</italic> = 9)</td><td align="left" rowspan="1" colspan="1">&#x025cf;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x025cf;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>o</bold></td><td align="left" rowspan="1" colspan="1"><bold>o</bold></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><xref rid="bib72" ref-type="bibr">Maertzdorf et al., 2012</xref></td><td align="left" rowspan="1" colspan="1">Germany</td><td align="left" rowspan="1" colspan="1">Whole blood</td><td align="left" rowspan="1" colspan="1">Active TB (<italic>n</italic> = 8); LTBI (<italic>n</italic> = 4); HC (<italic>n</italic> = 14)</td><td align="left" rowspan="1" colspan="1">&#x025cf;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>o</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>o</bold></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><xref rid="bib94" ref-type="bibr">Ottenhoff et al., 2012</xref></td><td align="left" rowspan="1" colspan="1">Indonesia</td><td align="left" rowspan="1" colspan="1">PBMCs</td><td align="left" rowspan="1" colspan="1">Active TB over time during treatment (<italic>n</italic> = 23); HC (<italic>n</italic> = 23)</td><td align="left" rowspan="1" colspan="1">&#x025cf;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x025cf;</td><td align="left" rowspan="1" colspan="1"><bold>o</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>o</bold></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><xref rid="bib18" ref-type="bibr">Cliff et al., 2013</xref></td><td align="left" rowspan="1" colspan="1">South Africa</td><td align="left" rowspan="1" colspan="1">Whole blood</td><td align="left" rowspan="1" colspan="1">Active TB over time during treatment (<italic>n</italic> = 27)</td><td align="left" rowspan="1" colspan="1">&#x025cf;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x025cf;</td><td align="left" rowspan="1" colspan="1"><bold>o</bold></td><td align="left" rowspan="1" colspan="1"><bold>o</bold></td><td align="left" rowspan="1" colspan="1"><bold>o</bold></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><xref rid="bib12" ref-type="bibr">Bloom et al., 2013</xref></td><td align="left" rowspan="1" colspan="1">UK</td><td align="left" rowspan="1" colspan="1">Whole blood (and sorted cells)</td><td align="left" rowspan="1" colspan="1">Active TB (<italic>n</italic> = 35); HCs (<italic>n</italic> = 113)</td><td align="left" rowspan="1" colspan="1">&#x025cf;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>o</bold></td><td align="left" rowspan="1" colspan="1"><bold>o</bold></td><td align="center" rowspan="1" colspan="1"><bold>o</bold></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><xref rid="bib64" ref-type="bibr">Kaforou et al., 2013</xref></td><td align="left" rowspan="1" colspan="1">South Africa, Malawi</td><td align="left" rowspan="1" colspan="1">Whole blood</td><td align="left" rowspan="1" colspan="1">Active TB (HIV&#x02212;/+; <italic>n</italic> = 195); LTBI (HIV&#x02212;/+; <italic>n</italic> = 167)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>o</bold></td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><bold>o</bold></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><xref rid="bib15" ref-type="bibr">Cai et al., 2014</xref></td><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">PBMCs</td><td align="left" rowspan="1" colspan="1">active TB (<italic>n</italic> = 9); LTBI (<italic>n</italic> = 6); HC (<italic>n</italic> = 6)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>o</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td rowspan="2" align="left" scope="row" colspan="1"><xref rid="bib3" ref-type="bibr">Anderson et al., 2014</xref></td><td align="left" rowspan="1" colspan="1">Kenya</td><td rowspan="2" align="left" colspan="1">Whole blood</td><td align="left" rowspan="1" colspan="1">Active TB (<italic>n</italic> = 79); LTBI (<italic>n</italic> = 14)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>o</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="1" align="left" scope="row" rowspan="1">South Africa, Malawi</td><td colspan="1" align="left" rowspan="1">Active TB (<italic>n</italic> = 110); LTBI (<italic>n</italic> = 54)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><bold>o</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><xref rid="bib102" ref-type="bibr">Roe et al., 2016</xref></td><td align="left" rowspan="1" colspan="1">UK</td><td align="left" rowspan="1" colspan="1">Whole blood</td><td align="left" rowspan="1" colspan="1">Active TB (<italic>n</italic> = 46); postrecovery (<italic>n</italic> = 31)</td><td align="left" rowspan="1" colspan="1">&#x025cf;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x025cf;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><xref rid="bib126" ref-type="bibr">Zak et al., 2016</xref></td><td align="left" rowspan="1" colspan="1">South Africa</td><td align="left" rowspan="1" colspan="1">Whole blood</td><td align="left" rowspan="1" colspan="1">Progressors (<italic>n</italic> = 40); nonprogressors (<italic>n</italic> = 104)</td><td align="left" rowspan="1" colspan="1">&#x025cf;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><bold>o</bold></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><xref rid="bib107" ref-type="bibr">Sambarey et al., 2017b</xref></td><td align="left" rowspan="1" colspan="1">India</td><td align="left" rowspan="1" colspan="1">Whole blood</td><td align="left" rowspan="1" colspan="1">Active TB (<italic>n</italic> = 19); LTBI (<italic>n</italic> = 13); HCs (<italic>n</italic> = 15)</td><td align="left" rowspan="1" colspan="1">&#x025cf;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><xref rid="bib111" ref-type="bibr">Singhania et al., 2017</xref></td><td align="left" rowspan="1" colspan="1">UK</td><td align="left" rowspan="1" colspan="1">Whole blood</td><td align="left" rowspan="1" colspan="1">Active TB (<italic>n</italic> = 53); LTBI (<italic>n</italic> = 49); HCs (<italic>n</italic> = 50)</td><td align="left" rowspan="1" colspan="1">&#x025cf;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><xref rid="bib42" ref-type="bibr">Esmail et al., 2018</xref></td><td align="left" rowspan="1" colspan="1">South Africa</td><td align="left" rowspan="1" colspan="1">Whole blood</td><td align="left" rowspan="1" colspan="1">Active TB (<italic>n</italic> = 15); subclinical TB (<italic>n</italic> = 10); latent TB (<italic>n</italic> = 25)</td><td align="left" rowspan="1" colspan="1">&#x025cf;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>Type I IFN signature reported in original study (&#x025cf;) and/or in subsequent analysis by others (o). HC, healthy control; LTBI, latent tuberculosis infection; PBMC, peripheral blood mononuclear cell; TB, tuberculosis.</p><fn specific-use="standard" id="ttbl1n2"><label>a</label><p>Original study providing the first data in human disease to support a role for type I IFN in the pathogenesis of tuberculosis. </p></fn></table-wrap-foot></table-wrap><p>Similar findings have since been observed in other mycobacterial infections. In human leprosy, caused by <italic>Myobacterium leprae</italic>, type I IFN and their downstream genes, were preferentially expressed in lesions of the disseminated and progressive lepromatous form at the site of disease, whereas IFN-&#x003b3; and its downstream genes were preferentially expressed in the lesions from patients with the self-healing tuberculoid form (<xref rid="bib115" ref-type="bibr">Teles et al., 2013</xref>). Overexpression of IFN-inducible genes in blood has also been reported in patients with other pulmonary diseases such as sarcoidosis and acute influenza infection but has not been detected in other bacterial infections (<xref rid="bib9" ref-type="bibr">Berry et al., 2010</xref>; <xref rid="bib72" ref-type="bibr">Maertzdorf et al., 2012</xref>; <xref rid="bib12" ref-type="bibr">Bloom et al., 2013</xref>; <xref rid="bib111" ref-type="bibr">Singhania et al., 2017</xref>). However, distinct gene patterns have been detected between tuberculosis and sarcoidosis (<xref rid="bib12" ref-type="bibr">Bloom et al., 2013</xref>) and tuberculosis and influenza infection (<xref rid="bib111" ref-type="bibr">Singhania et al., 2017</xref>).</p><p>In tuberculosis, overexpression of IFN response genes, including <italic>STAT1</italic>, <italic>IFITs</italic>, <italic>GBPs</italic>, <italic>MX1</italic>, <italic>OAS1</italic>, <italic>IRF1</italic>, and other genes, were also detected early in tuberculosis contacts who progressed to active disease (<xref rid="bib126" ref-type="bibr">Zak et al., 2016</xref>; <xref rid="bib108" ref-type="bibr">Scriba et al., 2017</xref>; <xref rid="bib111" ref-type="bibr">Singhania et al., 2017</xref>; <xref rid="bib42" ref-type="bibr">Esmail et al., 2018</xref>), suggesting that peripheral activation of the type I IFN response precedes the onset of active disease and clinical manifestations of tuberculosis. These changes apparently preceded the up-regulation of other innate immune responses and down-regulation of genes associated with specific lymphocyte cell populations (<xref rid="bib108" ref-type="bibr">Scriba et al., 2017</xref>; <xref rid="bib111" ref-type="bibr">Singhania et al., 2017</xref>), although this conclusion requires more detailed studies. The type I IFN&#x02013;inducible signature was also present in 10&#x02013;25% of latently infected patients who are asymptomatic (<xref rid="bib9" ref-type="bibr">Berry et al., 2010</xref>; <xref rid="bib111" ref-type="bibr">Singhania et al., 2017</xref>), suggesting that these patients may be at the highest risk to progress to active disease.</p><p>Several clinical studies have reported reactivation of tuberculosis in patients undergoing IFN-&#x003b1; based therapy for chronic viral hepatitis (<xref rid="bib104" ref-type="bibr">Sabbatani et al., 2006</xref>; <xref rid="bib43" ref-type="bibr">Farah and Awad, 2007</xref>; <xref rid="bib116" ref-type="bibr">Telesca et al., 2007</xref>; <xref rid="bib7" ref-type="bibr">Belkahla et al., 2010</xref>; <xref rid="bib57" ref-type="bibr">Guardigni et al., 2012</xref>; <xref rid="bib1" ref-type="bibr">Abutidze et al., 2016</xref>; <xref rid="bib32" ref-type="bibr">de Oliveira Uehara et al., 2016</xref>; <xref rid="bib77" ref-type="bibr">Matsuoka et al., 2016</xref>). In addition, a very recent study showed that impaired type I IFN signaling due to a rare East Asian functional mutation in the <italic>IFNAR1</italic> gene was associated with increased resistance to tuberculosis (<xref rid="bib128" ref-type="bibr">Zhang et al., 2018</xref>). As the control population consisted of healthy individuals, it is presently unclear whether this polymorphism influences susceptibility to infection as opposed to disease progression in latent infected individuals. In contrast, patients with an inherited deficiency in the gene encoding ISG15, who displayed immunological and clinical signs of enhanced type I IFN responses (<xref rid="bib129" ref-type="bibr">Zhang et al., 2015</xref>), were shown to be more susceptible to mycobacterial infections (<xref rid="bib13" ref-type="bibr">Bogunovic et al., 2012</xref>). Together, these findings provide strong evidence that type I IFN signaling correlates with impaired control of <italic>M. tuberculosis</italic> and other mycobacterial infections and underlies an increased risk of tuberculosis in humans.</p></sec><sec disp-level="2" id="s05"><title>Foe-like pathogenic role of high and sustained type I IFN in tuberculosis: Evidence from mouse models</title><p>Following on from the observations in human tuberculosis, whole-genome blood transcriptional profiling in animal models of tuberculosis have since shown up-regulation of type I IFN response related genes in response to <italic>M. tuberculosis</italic> infection in both nonhuman primates (<xref rid="bib53" ref-type="bibr">Gideon et al., 2016</xref>) and mice (<xref rid="bib39" ref-type="bibr">Domaszewska et al., 2017</xref>). However, different effects of type I IFN in either protection or pathogenesis in experimental models of tuberculosis have been reported as we discuss herein. Several studies have reported reduced bacterial loads (<xref rid="bib93" ref-type="bibr">Ordway et al., 2007</xref>; <xref rid="bib113" ref-type="bibr">Stanley et al., 2007</xref>; <xref rid="bib81" ref-type="bibr">Mayer-Barber et al., 2011</xref>; <xref rid="bib41" ref-type="bibr">Dorhoi et al., 2014</xref>) and/or improved host survival (<xref rid="bib74" ref-type="bibr">Manca et al., 2005</xref>; <xref rid="bib41" ref-type="bibr">Dorhoi et al., 2014</xref>; <xref rid="bib66" ref-type="bibr">Kimmey et al., 2017</xref>) upon <italic>M. tuberculosis</italic> infection of IFNAR-deficient (<italic>Ifnar1<sup>&#x02212;/&#x02212;</sup></italic>) mice compared with WT controls although this phenotype has not been universally observed (<xref rid="bib24" ref-type="bibr">Cooper et al., 2000</xref>; <xref rid="bib4" ref-type="bibr">Antonelli et al., 2010</xref>; <xref rid="bib34" ref-type="bibr">Desvignes et al., 2012</xref>; <xref rid="bib83" ref-type="bibr">McNab et al., 2013</xref>; <xref rid="bib100" ref-type="bibr">Redford et al., 2014</xref>; <xref rid="bib87" ref-type="bibr">Moreira-Teixeira et al., 2016</xref>, <xref rid="bib88" ref-type="bibr">2017</xref>). The reasons underlying the discrepancies in the results of these studies (summarized in <xref ref-type="table" rid="tbl2">Table 2</xref>) are presently unclear but may relate to differences in the <italic>M. tuberculosis</italic> strains used for challenge, host genetic background of the different colonies of <italic>Ifnar1<sup>&#x02212;/&#x02212;</sup></italic> mice used, or environmental differences.</p><table-wrap id="tbl2" orientation="portrait" position="float"><?Table Large?><label>Table 2.</label><caption><title>Summary of outcomes reported following aerosol infection with <italic>M. tuberculosis</italic> in <italic>Ifnar</italic><sup>&#x02212;/&#x02212;</sup> mice</title></caption><table frame="hsides" rules="groups"><col width="8%" span="1"/><col width="10%" span="1"/><col width="12%" span="1"/><col width="18%" span="1"/><col width="14%" span="1"/><col width="13%" span="1"/><col width="13%" span="1"/><col width="12%" span="1"/><thead><tr><th rowspan="2" align="left" scope="col" colspan="1"><italic>Mtb</italic> strain</th><th rowspan="2" align="left" scope="col" colspan="1">Dose (CFU)</th><th rowspan="2" align="left" scope="col" colspan="1">Mouse background</th><th colspan="2" align="left" scope="colgroup" rowspan="1">Bacterial loads<xref ref-type="table-fn" rid="ttbl2n2"><sup>a</sup></xref></th><th rowspan="2" align="left" scope="col" colspan="1">Lung pathology<xref ref-type="table-fn" rid="ttbl2n2"><sup>a</sup></xref></th><th rowspan="2" align="left" scope="col" colspan="1">Survival<xref ref-type="table-fn" rid="ttbl2n2"><sup>a</sup></xref></th><th rowspan="2" align="left" scope="col" colspan="1">Reference</th></tr><tr><th colspan="1" align="left" scope="colgroup" rowspan="1">Lung</th><th align="left" scope="col" rowspan="1" colspan="1">Spleen</th></tr></thead><tbody><tr><td align="left" scope="row" rowspan="1" colspan="1">H37Rv</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">C57BL/6 (R)</td><td align="left" rowspan="1" colspan="1">Increased (day 28 p.i.)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1"><xref rid="bib4" ref-type="bibr">Antonelli et al., 2010</xref></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">H37Rv</td><td align="left" rowspan="1" colspan="1">100&#x02013;150</td><td align="left" rowspan="1" colspan="1">C57BL/6 (R)</td><td align="left" rowspan="1" colspan="1">Decreased (day 28 p.i.)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1"><xref rid="bib81" ref-type="bibr">Mayer-Barber et al., 2011</xref></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">H37Rv</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">C57BL/6 (R)</td><td align="left" rowspan="1" colspan="1">Transiently decreased (day 18 p.i.) but similar at day 25 p.i.</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Similar (day 70 p.i.)</td><td align="left" rowspan="1" colspan="1"><xref rid="bib34" ref-type="bibr">Desvignes et al., 2012</xref></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">H37Rv</td><td align="left" rowspan="1" colspan="1">50&#x02013;150</td><td align="left" rowspan="1" colspan="1">C57BL/6 (R)</td><td align="left" rowspan="1" colspan="1">Similar (day 27 p.i.)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1"><bold>&#x02014;</bold></td><td align="left" rowspan="1" colspan="1"><xref rid="bib100" ref-type="bibr">Redford et al., 2014</xref></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">H37Rv</td><td align="left" rowspan="1" colspan="1">100&#x02013;150</td><td align="left" rowspan="1" colspan="1">C57BL/6 (R)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Similar (day 80 p.i.)</td><td align="left" rowspan="1" colspan="1"><xref rid="bib82" ref-type="bibr">Mayer-Barber et al., 2014</xref></td></tr><tr><td rowspan="2" align="left" scope="row" colspan="1">H37Rv</td><td align="left" rowspan="1" colspan="1">500 (200 for survival)</td><td align="left" rowspan="1" colspan="1">C57BL/6 (R)</td><td align="left" rowspan="1" colspan="1">Decreased (day 42 p.i.)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Similar (day 80 p.i.)</td><td rowspan="2" align="left" colspan="1"><xref rid="bib41" ref-type="bibr">Dorhoi et al., 2014</xref></td></tr><tr><td colspan="1" align="left" scope="row" rowspan="1">200</td><td align="left" rowspan="1" colspan="1">129S2 (S)</td><td align="left" rowspan="1" colspan="1">Decreased (day 21 p.i.)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Decreased (day 21 p.i.)</td><td align="left" rowspan="1" colspan="1">Increased</td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">H37Rv</td><td align="left" rowspan="1" colspan="1">50&#x02013;100</td><td align="left" rowspan="1" colspan="1">KO 129 (S); WT C57BL/6 (R)</td><td align="left" rowspan="1" colspan="1">Decreased (chronic phase, &#x0003e; day 75 p.i.)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1"><xref rid="bib93" ref-type="bibr">Ordway et al., 2007</xref></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Erdman</td><td align="left" rowspan="1" colspan="1">10<sup>6</sup> (i.v.)</td><td align="left" rowspan="1" colspan="1">C57BL/6 (R)</td><td align="left" rowspan="1" colspan="1">Similar (days 10, 21 p.i.)</td><td align="left" rowspan="1" colspan="1">Decreased (days 10, 21 p.i.)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1"><xref rid="bib113" ref-type="bibr">Stanley et al., 2007</xref></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Erdman</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">C57BL/6 (R)</td><td align="left" rowspan="1" colspan="1">Transiently decreased (day 7 p.i.) but similar at days 21, 77, 100, 245 p.i.</td><td align="left" rowspan="1" colspan="1">Transiently decreased at day 77 p.i. but similar at other time points</td><td align="left" rowspan="1" colspan="1">Similar (days 100, 275 p.i.)</td><td align="left" rowspan="1" colspan="1">Increased</td><td align="left" rowspan="1" colspan="1"><xref rid="bib66" ref-type="bibr">Kimmey et al., 2017</xref></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Erdman</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">B6/129 (S)</td><td align="left" rowspan="1" colspan="1">Transiently increased (days 10, 20, 40 p.i.) but similar by day 80 p.i.</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1"><xref rid="bib24" ref-type="bibr">Cooper et al., 2000</xref></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">Erdman</td><td align="left" rowspan="1" colspan="1">50&#x02013;100</td><td align="left" rowspan="1" colspan="1">KO 129 (S); WT C57BL/6 (R)</td><td align="left" rowspan="1" colspan="1">Decreased (&#x0003e; day 25 p.i.)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Similar (day 200 p.i.)</td><td align="left" rowspan="1" colspan="1"><xref rid="bib93" ref-type="bibr">Ordway et al., 2007</xref></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">CSU93</td><td align="left" rowspan="1" colspan="1">50&#x02013;100</td><td align="left" rowspan="1" colspan="1">KO 129 (S); WT C57BL/6 (R)</td><td align="left" rowspan="1" colspan="1">Decreased (&#x0003e; day 25 p.i.)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Similar (day 200 p.i.)</td><td align="left" rowspan="1" colspan="1"><xref rid="bib93" ref-type="bibr">Ordway et al., 2007</xref></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">HN878</td><td align="left" rowspan="1" colspan="1">100&#x02013;200</td><td align="left" rowspan="1" colspan="1">C57BL/6 (R)</td><td align="left" rowspan="1" colspan="1">Similar (days 28, 60 p.i.)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1"><xref rid="bib88" ref-type="bibr">Moreira-Teixeira et al., 2017</xref></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">HN878</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">C57BL/6 (R)</td><td align="left" rowspan="1" colspan="1">Similar (day 48 p.i.)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1"><xref rid="bib83" ref-type="bibr">McNab et al., 2013</xref></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">HN878</td><td align="left" rowspan="1" colspan="1">100&#x02013;200</td><td align="left" rowspan="1" colspan="1">129 (S)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Increased</td><td align="left" rowspan="1" colspan="1"><xref rid="bib74" ref-type="bibr">Manca et al., 2005</xref></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">HN878</td><td align="left" rowspan="1" colspan="1">50&#x02013;100</td><td align="left" rowspan="1" colspan="1">KO 129 (S); WT C57BL/6 (R)</td><td align="left" rowspan="1" colspan="1">Decreased (&#x0003e; day 50 p.i.)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Similar (day 200 p.i.)</td><td align="left" rowspan="1" colspan="1"><xref rid="bib93" ref-type="bibr">Ordway et al., 2007</xref></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">BTB 02-171</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">C57BL/6 (R)</td><td align="left" rowspan="1" colspan="1">Similar (day 56 p.i.)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1"><xref rid="bib83" ref-type="bibr">McNab et al., 2013</xref></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1">BTB 02-171</td><td align="left" rowspan="1" colspan="1">100&#x02013;200</td><td align="left" rowspan="1" colspan="1">C57BL/6 (R)</td><td align="left" rowspan="1" colspan="1">Similar (days 20, 24, 27 p.i.)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">Similar (day 27 p.i.)</td><td align="left" rowspan="1" colspan="1">Similar (&#x0003e; day 200 p.i.)</td><td align="left" rowspan="1" colspan="1"><xref rid="bib87" ref-type="bibr">Moreira-Teixeira et al., 2016</xref></td></tr></tbody></table><table-wrap-foot><p>Dashes indicate no data reported. <italic>Mtb</italic>, <italic>M. tuberculosis</italic>; p.i., postinfection; (R), <italic>M. tuberculosis</italic>&#x02013;resistant mouse strain; (S), <italic>M. tuberculosis</italic>&#x02013;susceptible mouse strain.</p><fn specific-use="standard" id="ttbl2n2"><label>a</label><p>Compared with WT mice.</p></fn></table-wrap-foot></table-wrap><p>Elevated production of type I IFN has been associated with the virulence of <italic>M. tuberculosis</italic> strains and increased host susceptibility. Studies of infection with hypervirulent <italic>M. tuberculosis</italic> clinical isolates (e.g., HN878 and BTB 02&#x02013;171) compared with the less virulent laboratory strain (H37Rv) showed a positive correlation between increased levels of type I IFN and increased mycobacterial virulence (<xref rid="bib73" ref-type="bibr">Manca et al., 2001</xref>, <xref rid="bib74" ref-type="bibr">2005</xref>; <xref rid="bib93" ref-type="bibr">Ordway et al., 2007</xref>; <xref rid="bib16" ref-type="bibr">Carmona et al., 2013</xref>). However, similar bacterial loads and survival were reported in <italic>Ifnar1<sup>&#x02212;/&#x02212;</sup></italic> and WT controls in the <italic>M. tuberculosis&#x02013;</italic>resistant C57BL/6 genetic background (<xref rid="bib83" ref-type="bibr">McNab et al., 2013</xref>; <xref rid="bib88" ref-type="bibr">Moreira-Teixeira et al., 2017</xref>). IFNAR deficiency in mice with a <italic>M. tuberculosis&#x02013;</italic>susceptible genetic background (A129, 129S2) enhanced host survival following infection with not only the hypervirulent strain HN878 (<xref rid="bib74" ref-type="bibr">Manca et al., 2005</xref>) but also the less virulent H37Rv strain (<xref rid="bib41" ref-type="bibr">Dorhoi et al., 2014</xref>). A stronger up-regulation of type I IFN response related genes has recently been reported in the blood of the highly susceptible 129S2 mouse strain compared with the resistant C57BL/6 mouse strain early after infection with the <italic>M. tuberculosis</italic> strain H37Rv (<xref rid="bib39" ref-type="bibr">Domaszewska et al., 2017</xref>). This increased expression of type I IFN&#x02013;inducible genes detected in 129S2 compared with C57BL/6 mice is consistent with the results showing that the detrimental effect of type I IFN during <italic>M. tuberculosis</italic> (laboratory strain H37Rv) infection is more pronounced in the highly susceptible 129S2 strain than the resistant C57BL/6 strain (<xref rid="bib41" ref-type="bibr">Dorhoi et al., 2014</xref>). However, a transient protective effect of type I IFN has also been observed during <italic>M. tuberculosis</italic> (Erdmann strain) infection using the 129 strain (<xref rid="bib24" ref-type="bibr">Cooper et al., 2000</xref>). Differing findings may relate to the genetic variation among 129 substrains (<xref rid="bib110" ref-type="bibr">Simpson et al., 1997</xref>; <xref rid="bib44" ref-type="bibr">Festing et al., 1999</xref>) in addition to <italic>M. tuberculosis</italic> strain type and the host environment. Experiments in which <italic>Ifnar1<sup>&#x02212;/&#x02212;</sup></italic> mice of either susceptible or resistant genetic backgrounds are studied side by side are needed to investigate the basis of the discrepancy across all the studies.</p><p>Robust evidence for the role of high and sustained levels of type I IFN in <italic>M. tuberculosis</italic> persistence and disease pathogenesis has been further provided by experimental models of type I IFN overexpression. Direct instillation of purified murine IFN-&#x003b1;/&#x003b2; into the lungs of <italic>M. tuberculosis&#x02013;</italic>infected B6D2/F1 mice resulted in increased lung bacterial loads and reduced survival of infected mice (<xref rid="bib73" ref-type="bibr">Manca et al., 2001</xref>). Prolonged induction of high levels of type I IFN by intranasal administration of the TLR3 ligand poly-ICLC during <italic>M. tuberculosis</italic> infection impaired control of bacterial growth and exacerbated pulmonary immunopathology in WT mice, but not in <italic>Ifnar<sup>&#x02212;/&#x02212;</sup></italic> mice (<xref rid="bib4" ref-type="bibr">Antonelli et al., 2010</xref>; <xref rid="bib82" ref-type="bibr">Mayer-Barber et al., 2014</xref>). Host coinfection with influenza A virus, another well-known inducer of type I IFN, has also been shown to reduce host resistance to <italic>M. tuberculosis</italic> infection via the action of type I IFN, because this was observed in WT, but not in IFNAR-deficient, mice (<xref rid="bib100" ref-type="bibr">Redford et al., 2014</xref>). Likewise, abrogation of negative regulators of type I IFN signaling leading to elevated levels of type I IFN resulted in impaired <italic>M. tuberculosis</italic> clearance (<xref rid="bib83" ref-type="bibr">McNab et al., 2013</xref>; <xref rid="bib27" ref-type="bibr">Dauphinee et al., 2014</xref>). Specifically, deletion of the MAPK kinase kinase 8 (MAP3K8; also known as TPL2), a negative regulator of type I IFN induction downstream of TLR, resulted in increased bacterial loads upon <italic>M. tuberculosis</italic> or <italic>L. monocytogenes</italic> infection, which was not observed in the absence of IFNAR (<xref rid="bib83" ref-type="bibr">McNab et al., 2013</xref>). Impaired control of the bacterial loads in the absence of TPL2 was correlated with type I IFN&#x02013;dependent induction of IL-10 and suppression of IL-12 production during infection (<xref rid="bib83" ref-type="bibr">McNab et al., 2013</xref>). Mice carrying a loss-of function mutation within the <italic>ubiquitin-specific peptidase 18</italic> (<italic>Usp18</italic>) gene, which results in increased levels of type I IFN production and hyperactivation of type I IFN signaling during bacterial infection, were also shown to be more susceptible to <italic>M. tuberculosis</italic> infection, showing increased bacterial burdens and decreased survival (<xref rid="bib27" ref-type="bibr">Dauphinee et al., 2014</xref>). Collectively, these studies performed in experimental mouse models of <italic>M. tuberculosis</italic> infection point to a detrimental role of high and sustained levels of type I IFN in exacerbating tuberculosis.</p></sec><sec disp-level="2" id="s06"><title>Mechanisms of type I IFN induction in <italic>M. tuberculosis</italic> infection</title><p>Because type I IFN has been associated with disease pathogenesis, identifying mechanisms regulating type I IFN induction during <italic>M. tuberculosis</italic> infection has been an active area of research (<xref rid="bib40" ref-type="bibr">Donovan et al., 2017</xref>; <xref rid="bib105" ref-type="bibr">Sabir et al., 2017</xref>). In vitro studies in human and murine cells have shown that distinct mycobacterial molecules and signaling pathways may be involved in the induction of this family of cytokines during <italic>M. tuberculosis</italic> infection (<xref ref-type="fig" rid="fig1">Fig. 1</xref>). High levels of type I IFN are preferentially induced by virulent strains of <italic>M. tuberculosis</italic> (<xref rid="bib73" ref-type="bibr">Manca et al., 2001</xref>, <xref rid="bib74" ref-type="bibr">2005</xref>; <xref rid="bib91" ref-type="bibr">Novikov et al., 2011</xref>; <xref rid="bib16" ref-type="bibr">Carmona et al., 2013</xref>), and this property seems to depend on the well-known mycobacterial virulence factor ESX-1 protein secretion system (<xref rid="bib113" ref-type="bibr">Stanley et al., 2007</xref>; <xref rid="bib76" ref-type="bibr">Manzanillo et al., 2012</xref>; <xref rid="bib120" ref-type="bibr">Wassermann et al., 2015</xref>).</p><fig id="fig1" fig-type="figure" orientation="portrait" position="float"><?Figure Large?><label>Figure 1.</label><caption><p><bold>Alternative pathways of type I IFN induction during <italic>M. tuberculosis</italic> infection.</bold> Recognition of mycobacterial products by a range of cell surface and cytosolic PRR, including TLR4, NOD2, and STING, activates the kinase TBK1 leading to phosphorylation (P) and dimerization of IRF3 or IRF5, which translocates into the nucleus and promotes transcription of type I IFN genes. Release of mycobacterial or mitochondrial DNA in the cytosol activates cGAS, which synthesizes cGAMP. Host-derived cGAMP and/or mycobacterial-derived c-di-AMP activates the STING pathway and the downstream TBK1&#x02013;IRF3 signaling axis. Peptidoglycan fragments can be sensed by NOD2 in the cytosol, activating the TBK1&#x02013;IRF5 signaling pathway. Detection of extracellular <italic>M. tuberculosis</italic> and/or its products by TLR4 triggers TRIF-TBK1-IRF3&#x02013;dependent induction of type I IFN by certain strains. Mtb, <italic>M. tuberculosis;</italic> mtDNA, mitochondrial DNA; PGN, peptidoglycan.</p></caption><graphic xlink:href="JEM_20180325_Fig1"/></fig><p>Recognition of mycobacterial products in the cytosol, such as peptidoglycan fragments, by the cytosolic sensor nucleotide-binding oligomerization containing protein 2 (NOD2) has been shown to induce type I IFN expression by infected murine macrophages (<xref rid="bib69" ref-type="bibr">Leber et al., 2008</xref>; <xref rid="bib96" ref-type="bibr">Pandey et al., 2009</xref>). NOD2 activates the downstream serine/threonine-protein kinase (TBK1)&#x02013;IFN regulatory factor 5 (IRF5) signaling pathway, leading to the production of type I IFN (<xref rid="bib96" ref-type="bibr">Pandey et al., 2009</xref>). Three independent studies have identified a central role for the cytosolic DNA sensor nucleotidyltransferase cyclic GMP-AMP synthase (cGAS) in the detection of mycobacterial DNA in the host cytosol and induction of type I IFN transcription in macrophages (<xref rid="bib19" ref-type="bibr">Collins et al., 2015</xref>; <xref rid="bib120" ref-type="bibr">Wassermann et al., 2015</xref>; <xref rid="bib121" ref-type="bibr">Watson et al., 2015</xref>). The sensing of DNA by cGAS leads to the synthesis of the second messenger cyclic di&#x02013;GMP-AMP (cGAMP), which activates the stimulator of IFN genes (STING) and the downstream TBK1&#x02013;IRF3 signaling pathway, culminating in the transcription of type I IFN (<xref rid="bib76" ref-type="bibr">Manzanillo et al., 2012</xref>; <xref rid="bib19" ref-type="bibr">Collins et al., 2015</xref>; <xref rid="bib120" ref-type="bibr">Wassermann et al., 2015</xref>; <xref rid="bib121" ref-type="bibr">Watson et al., 2015</xref>). Mycobacterial DNA in the host cytosol can also be sensed by absent in melanoma 2 (AIM-2) protein, which partially contributes to the activation of the NLRP3-inflammasome, promoting the maturation of the protective cytokine IL-1&#x003b2; (<xref rid="bib109" ref-type="bibr">Shah et al., 2013</xref>; <xref rid="bib120" ref-type="bibr">Wassermann et al., 2015</xref>). This AIM-2&#x02013;IL-1&#x003b2; signaling pathway has been recently reported to negatively regulate the STING-dependent type I IFN production in macrophages and dendritic cells (DCs) by inhibiting the association between STING and TBK1 (<xref rid="bib125" ref-type="bibr">Yan et al., 2018</xref>).</p><p>A more recent study suggested that cGAS/STING&#x02013;dependent type I IFN induction in macrophages can also be triggered by mitochondrial DNA released into the cytosol due to mitochondrial stress caused by <italic>M. tuberculosis</italic> infection (<xref rid="bib122" ref-type="bibr">Wiens and Ernst, 2016</xref>). Production of cyclic di-AMP (c-di-AMP) by <italic>M. tuberculosis</italic> has also been shown to promote type I IFN induction in a STING-dependent but cGAS-independent mechanism (<xref rid="bib36" ref-type="bibr">Dey et al., 2015</xref>). STING-dependent induction of type I IFN can be regulated by mycobacterial and host phosphodiesterases, which inhibit STING activation and consequent induction of type I IFN by hydrolysis of both mycobacterial-derived c-di-AMP and host-derived cGAMP (<xref rid="bib37" ref-type="bibr">Dey et al., 2017</xref>).</p><p>TLRs are another set of pattern recognition receptors (PRRs) that are important for sensing <italic>M. tuberculosis</italic> infection (<xref rid="bib112" ref-type="bibr">Stamm et al., 2015</xref>). Whereas some <italic>M. tuberculosis</italic> strains activate mainly TLR2, others also activate TLR4 and the downstream MyD88-independent TIR domain&#x02013;containing adapter-inducing IFN-&#x003b2; (TRIF), resulting in different macrophage responses characterized by varying production of type I IFN (<xref rid="bib16" ref-type="bibr">Carmona et al., 2013</xref>; <xref rid="bib87" ref-type="bibr">Moreira-Teixeira et al., 2016</xref>). Sensing of <italic>M. tuberculosis</italic> infection by C-type lectin receptors has also been reported to induce type I IFN production by B cells (<xref rid="bib8" ref-type="bibr">Benard et al., 2017</xref>) and to amplify type I IFN responses in DCs (<xref rid="bib118" ref-type="bibr">Troegeler et al., 2017</xref>). In B cells, induction of type I IFN during <italic>M. tuberculosis</italic> infection has also been shown to require the STING signaling pathway and to be negatively regulated by MyD88 (<xref rid="bib8" ref-type="bibr">Benard et al., 2017</xref>).</p><p>These studies indicate that different <italic>M. tuberculosis</italic> strains can induce type I IFN by triggering multiple cell surface and cytosolic PRR and downstream signaling pathways (<xref ref-type="fig" rid="fig1">Fig. 1</xref>), which may contribute to the differential levels of type I IFN and virulence induced by distinct strains. Further studies are required to determine the relative importance of each of these pathways in vivo and determine how widely they function in different cell types, as they could provide novel targets for tuberculosis prevention and therapy.</p></sec><sec disp-level="2" id="s07"><title>Pathogenic effects of type I IFN signaling during <italic>M. tuberculosis</italic> infection</title><p>Studies performed in patients and mouse models of infection collectively point to a harmful role of high and sustained type I IFN in tuberculosis (discussed above). However, the mechanisms by which type I IFN signaling exacerbates <italic>M. tuberculosis</italic> infection are not yet fully understood (<xref rid="bib78" ref-type="bibr">Mayer-Barber and Sher, 2015</xref>; <xref rid="bib85" ref-type="bibr">McNab et al., 2015</xref>; <xref rid="bib40" ref-type="bibr">Donovan et al., 2017</xref>; <xref rid="bib105" ref-type="bibr">Sabir et al., 2017</xref>). Early studies with hypervirulent strains of <italic>M. tuberculosis</italic> associated the induction of higher levels of type I IFN with the suppression of proinflammatory cytokines and impaired antibacterial Th1 responses (<xref rid="bib73" ref-type="bibr">Manca et al., 2001</xref>, <xref rid="bib74" ref-type="bibr">2005</xref>; <xref rid="bib93" ref-type="bibr">Ordway et al., 2007</xref>). The inhibition of host-protective cytokines and innate cell responsiveness in addition to IFN-&#x003b3;&#x02013;driven antibacterial effects by type I IFN has since been verified by several other studies both in human cells (<xref rid="bib81" ref-type="bibr">Mayer-Barber et al., 2011</xref>; <xref rid="bib91" ref-type="bibr">Novikov et al., 2011</xref>; <xref rid="bib33" ref-type="bibr">de Paus et al., 2013</xref>; <xref rid="bib115" ref-type="bibr">Teles et al., 2013</xref>) and mouse models (<xref rid="bib81" ref-type="bibr">Mayer-Barber et al., 2011</xref>; <xref rid="bib83" ref-type="bibr">McNab et al., 2013</xref>, <xref rid="bib84" ref-type="bibr">2014</xref>; <xref rid="bib41" ref-type="bibr">Dorhoi et al., 2014</xref>). In addition, type I IFN has also been shown to promote early cell death of alveolar macrophages (<xref rid="bib41" ref-type="bibr">Dorhoi et al., 2014</xref>) and boost the local accumulation of permissive myeloid cells, which contribute to the spread of infection and pulmonary inflammation (<xref rid="bib4" ref-type="bibr">Antonelli et al., 2010</xref>; <xref rid="bib41" ref-type="bibr">Dorhoi et al., 2014</xref>), underlining the complex role of type I IFN during <italic>M. tuberculosis</italic> infection (<xref ref-type="fig" rid="fig2">Fig. 2</xref>).</p><fig id="fig2" fig-type="figure" orientation="portrait" position="float"><?Figure Large?><label>Figure 2.</label><caption><p><bold>Foe- and friendly-like effects of type I IFN during <italic>M. tuberculosis</italic> infection.</bold> Type I IFN has been reported to play both negative (red arrows) and positive (green arrows) functions during <italic>M. tuberculosis</italic> infection. <bold>(A)</bold> Tonic levels of autocrine type I IFN signaling prime the production of protective cytokines IL-12 and TNF-&#x003b1;. <bold>(B)</bold> However, high and sustained levels of type I IFN promote the production of IL-10 and inhibit the production of protective cytokines IL-12, TNF-&#x003b1;, IL-1&#x003b1;, and IL-1&#x003b2;. IL-10 mediates a suppressive feedback loop, contributing to the decreased production of IL-12 and TNF-&#x003b1;. Type I IFN also inhibits myeloid cell responsiveness to IFN-&#x003b3; by both IL-10&#x02013;dependent and independent mechanisms, suppressing IFN-&#x003b3;&#x02013;dependent host-protective immune responses. In addition, type I IFN can promote cell death in alveolar macrophages and accumulation of permissive myeloid cells at the site of infection. <bold>(C)</bold> In the absence of the IFN-&#x003b3; receptor, type I IFN inhibits <italic>Arg1</italic> expression directly or indirectly by increasing TNF-&#x003b1; levels, thus regulating macrophage activation toward a more protective phenotype. Type I IFN signaling can also promote the recruitment, differentiation, and/or survival of protective myeloid cells that control pathology at the site of infection. <italic>Arg1</italic>, arginase 1; IFN&#x003b3;R, IFN-&#x003b3; receptor; IL-10R, IL-10 receptor; TNFR, TNF-&#x003b1; receptor.</p></caption><graphic xlink:href="JEM_20180325_Fig2"/></fig><p>Type I IFN has been reported to inhibit the production of IL-1&#x003b1; and IL-1&#x003b2;, which are critical for host defense against <italic>M. tuberculosis</italic> infection (<xref rid="bib80" ref-type="bibr">Mayer-Barber et al., 2010</xref>, <xref rid="bib81" ref-type="bibr">2011</xref>), both in vitro in infected human (<xref rid="bib81" ref-type="bibr">Mayer-Barber et al., 2011</xref>; <xref rid="bib91" ref-type="bibr">Novikov et al., 2011</xref>; <xref rid="bib33" ref-type="bibr">de Paus et al., 2013</xref>) and mouse myeloid cells (<xref rid="bib81" ref-type="bibr">Mayer-Barber et al., 2011</xref>; <xref rid="bib84" ref-type="bibr">McNab et al., 2014</xref>) and in vivo in mouse models (<xref rid="bib81" ref-type="bibr">Mayer-Barber et al., 2011</xref>; <xref rid="bib41" ref-type="bibr">Dorhoi et al., 2014</xref>). Prostaglandin E2 (PGE2) has been shown to be a critical downstream mediator of IL-1&#x02013;dependent host resistance, and accordingly, type I IFN has been shown to limit PGE2 in vitro in human and mouse cells and in vivo (<xref rid="bib82" ref-type="bibr">Mayer-Barber et al., 2014</xref>). PGE2 is known to prevent necrosis of <italic>M. tuberculosis</italic>&#x02013;infected macrophages by promoting apoptosis, a cell death modality that contains the pathogen, limiting its dissemination (<xref rid="bib17" ref-type="bibr">Chen et al., 2008</xref>; <xref rid="bib38" ref-type="bibr">Divangahi et al., 2009</xref>). Thus, an additional mechanism by which type I IFN could enhance <italic>M. tuberculosis</italic> infection and disease is through promotion of necrosis as a consequence of PGE2 inhibition.</p><p>In turn, it has recently been demonstrated that there is a reciprocal control of type I IFN regulation by IL-1&#x003b2; through a PGE2-mediated mechanism (<xref rid="bib82" ref-type="bibr">Mayer-Barber et al., 2014</xref>). Increasing the levels of PGE2 during <italic>M. tuberculosis</italic> infection, by direct administration of this prostanoid or by increasing its level through 5-lipoxygenase blockade with zileuton, limited type I IFN induction and conferred host resistance to infection in mice (<xref rid="bib82" ref-type="bibr">Mayer-Barber et al., 2014</xref>). These findings suggest zileuton as a drug that could be used for host-directed therapy of tuberculosis by limiting detrimental type I IFN overproduction.</p><p>The production of other proinflammatory cytokines such as TNF-&#x003b1; and IL-12 has also been shown to be negatively affected by the addition of exogenous IFN-&#x003b1; or IFN-&#x003b2; to human monocytes (<xref rid="bib33" ref-type="bibr">de Paus et al., 2013</xref>) and murine macrophages (<xref rid="bib84" ref-type="bibr">McNab et al., 2014</xref>) in in vitro cultures. Type I IFN has also been reported to induce the production of the immunosuppressive cytokine IL-10 in vitro in macrophages (<xref rid="bib81" ref-type="bibr">Mayer-Barber et al., 2011</xref>; <xref rid="bib84" ref-type="bibr">McNab et al., 2014</xref>) and in vivo in CD4<sup>+</sup> T cells (<xref rid="bib88" ref-type="bibr">Moreira-Teixeira et al., 2017</xref>), which has been shown to increase susceptibility to <italic>M. tuberculosis</italic> infection (<xref rid="bib99" ref-type="bibr">Redford et al., 2011</xref>). In addition, the increased susceptibility of <italic>M. tuberculosis</italic>&#x02013;infected mice given the double-stranded RNA homologue poly-ICLC, which led to enhanced type I IFN production, was shown to be dependent on IL-10 production (<xref rid="bib82" ref-type="bibr">Mayer-Barber et al., 2014</xref>). The inhibitory effect of type I IFN on the production of IL-12 and TNF-&#x003b1; by <italic>M. tuberculosis</italic>&#x02013;infected macrophages is abrogated in the absence of IL-10 (<xref rid="bib84" ref-type="bibr">McNab et al., 2014</xref>). However, the inhibitory effect of type I IFN on IL-1&#x003b2; production is only slightly affected by IL-10 deficiency (<xref rid="bib81" ref-type="bibr">Mayer-Barber et al., 2011</xref>; <xref rid="bib84" ref-type="bibr">McNab et al., 2014</xref>), indicating that type I IFN suppresses the macrophage response to <italic>M. tuberculosis</italic> infection by both IL-10&#x02013;dependent and &#x02013;independent mechanisms.</p><p>In addition, type I IFN has been shown to repress macrophage/monocyte responsiveness to the antibacterial effects of IFN-&#x003b3; during mycobacterial infections (<xref rid="bib33" ref-type="bibr">de Paus et al., 2013</xref>; <xref rid="bib115" ref-type="bibr">Teles et al., 2013</xref>; <xref rid="bib84" ref-type="bibr">McNab et al., 2014</xref>). In both mouse and human cells, type I IFN has been shown to suppress the ability of monocytes and macrophages to up-regulate antimycobacterial effector molecules and to restrict bacterial growth in response to both <italic>M. tuberculosis</italic> and <italic>M. leprae</italic> (<xref rid="bib115" ref-type="bibr">Teles et al., 2013</xref>; <xref rid="bib84" ref-type="bibr">McNab et al., 2014</xref>). This inhibitory effect of type I IFN on the antimycobacterial activity of IFN-&#x003b3; in human macrophages has shown to be mediated by IL-10 (<xref rid="bib115" ref-type="bibr">Teles et al., 2013</xref>). However, the inhibition of IFN-&#x003b3;&#x02013;induced cytokine production by type I IFN in murine macrophages seems to be mediated by both IL-10&#x02013;dependent and &#x02013;independent mechanisms (<xref rid="bib84" ref-type="bibr">McNab et al., 2014</xref>). Down-regulation of IFN-&#x003b3;&#x02013;driven inducible nitric oxide synthase and IL-12/23 p40 by type I IFN has also been reported in lung myeloid cells during <italic>M. tuberculosis</italic> infection in vivo (<xref rid="bib81" ref-type="bibr">Mayer-Barber et al., 2011</xref>; <xref rid="bib78" ref-type="bibr">Mayer-Barber and Sher, 2015</xref>). Although induction of IL-10 by type I IFN has been reported during <italic>M. tuberculosis</italic> infection in vivo (<xref rid="bib88" ref-type="bibr">Moreira-Teixeira et al., 2017</xref>), it is not yet clear whether IL-10 is responsible for the suppressive effects of type I IFN on IFN-&#x003b3; function in vivo.</p></sec><sec disp-level="2" id="s08"><title>Friendly protective functions of type I IFN in tuberculosis</title><p>Although a role for type I IFN in the pathogenesis of tuberculosis is strongly supported by studies in both human tuberculosis (<xref rid="bib128" ref-type="bibr">Zhang et al., 2018</xref>) and studies in experimental mouse models of <italic>M. tuberculosis</italic> infection (<xref rid="bib4" ref-type="bibr">Antonelli et al., 2010</xref>; <xref rid="bib83" ref-type="bibr">McNab et al., 2013</xref>; <xref rid="bib41" ref-type="bibr">Dorhoi et al., 2014</xref>; <xref rid="bib82" ref-type="bibr">Mayer-Barber et al., 2014</xref>; <xref rid="bib100" ref-type="bibr">Redford et al., 2014</xref>), there is also evidence that type I IFN can display protective functions under specific conditions. Several clinical case reports have described improved clinical symptoms and decreased bacterial burden after coadministration of IFN-&#x003b1; together with antimycobacterial chemotherapy to patients with active tuberculosis who were not responsive to conventional treatment and/or had recurrent disease (<xref rid="bib54" ref-type="bibr">Giosu&#x000e9; et al., 1998</xref>; <xref rid="bib95" ref-type="bibr">Palmero et al., 1999</xref>; <xref rid="bib55" ref-type="bibr">Giosu&#x000e8; et al., 2000</xref>; <xref rid="bib75" ref-type="bibr">Mansoori et al., 2002</xref>; <xref rid="bib127" ref-type="bibr">Zarogoulidis et al., 2012</xref>). These clinical studies of IFN-&#x003b1; adjunct therapy were designed before the now numerous studies linking type I IFN expression with active tuberculosis, and the mechanisms underlying the beneficial effects of IFN-&#x003b1; administration in these patients remain unclear. Therapeutic effects of IFN-&#x003b1; have also been reported in young patients suffering from mycobacterial infections with complete or partial IFN-&#x003b3; receptor (IFNGR) signaling deficiencies when administered together with antimycobacterial chemotherapy (<xref rid="bib119" ref-type="bibr">Ward et al., 2007</xref>; <xref rid="bib6" ref-type="bibr">Bax et al., 2013</xref>).</p><p>A protective role for type I IFN in the absence of IFN-&#x003b3; signaling has also been proposed in mouse models of <italic>M. tuberculosis</italic> infection (<xref rid="bib34" ref-type="bibr">Desvignes et al., 2012</xref>; <xref rid="bib87" ref-type="bibr">Moreira-Teixeira et al., 2016</xref>), suggesting that the dominant suppressive effect of type I IFN on IFN-&#x003b3; antimycobacterial activity may mask potentially protective functions of this family of cytokines (<xref ref-type="fig" rid="fig2">Fig. 2</xref>). These studies reported increased pulmonary pathology and early mortality following <italic>M. tuberculosis</italic> infection in mice deficient in both type I IFN and IFN-&#x003b3; receptors (<italic>Ifngr1</italic><sup>&#x02212;/&#x02212;</sup><italic>Ifnar1</italic><sup>&#x02212;/&#x02212;</sup>) compared with single IFNGR-deficient mice (<italic>Ifngr1</italic><sup>&#x02212;/&#x02212;</sup>; <xref rid="bib34" ref-type="bibr">Desvignes et al., 2012</xref>; <xref rid="bib87" ref-type="bibr">Moreira-Teixeira et al., 2016</xref>). In contrast to what has been reported in the immunocompetent host, where type I IFN signaling may promote local accumulation of permissive myeloid cells that contribute to the spread of infection and pulmonary inflammation (<xref rid="bib4" ref-type="bibr">Antonelli et al., 2010</xref>; <xref rid="bib41" ref-type="bibr">Dorhoi et al., 2014</xref>), in the absence of IFN-&#x003b3; signaling, type I IFN may facilitate the recruitment, differentiation, and/or survival of myeloid cells that control pathology (<xref rid="bib34" ref-type="bibr">Desvignes et al., 2012</xref>). Although no difference in the lung bacterial burden was observed during infection with the less virulent laboratory strain H37Rv (<xref rid="bib34" ref-type="bibr">Desvignes et al., 2012</xref>), infection with the hypervirulent strain BTB 02&#x02013;171, shown to induce high levels of type I IFN (<xref rid="bib16" ref-type="bibr">Carmona et al., 2013</xref>), revealed the ability of type I IFN to also control bacterial replication (<xref rid="bib87" ref-type="bibr">Moreira-Teixeira et al., 2016</xref>). Following infection with BTB 02&#x02013;171, increased lung bacterial loads were observed in double <italic>Ifngr1</italic><sup>&#x02212;/&#x02212;</sup><italic>Ifnar1</italic><sup>&#x02212;/&#x02212;</sup> mice, which are deficient in both type I IFN and IFN-&#x003b3; receptors, compared with single <italic>Ifngr1</italic><sup>&#x02212;/&#x02212;</sup>mice. Increased control of bacterial replication in the absence of IFN-&#x003b3; signaling correlated with suppression of alternative macrophage activation by type I IFN, likely by direct regulation of macrophage activation as well as by regulation of cytokine expression in the infected lungs (<xref rid="bib87" ref-type="bibr">Moreira-Teixeira et al., 2016</xref>). These findings may help to explain some of the mechanisms underlying the beneficial effects of IFN-&#x003b1; treatment, at least in patients with compromised IFN-&#x003b3; responses, and provide new avenues for host-directed therapies in tuberculosis.</p><p>Type I IFN has also been reported to increase host resistance in mouse models of infection against avirulent mycobacterial strains, such as <italic>Mycobacterium smegmatis</italic> (<xref rid="bib103" ref-type="bibr">Ruangkiattikul et al., 2017</xref>), <italic>Mycobacterium avium</italic> (<xref rid="bib31" ref-type="bibr">Denis, 1991</xref>), and <italic>Mycobacterium bovis</italic> bacillus Calmette-Gu&#x000e9;rin (BCG; <xref rid="bib67" ref-type="bibr">Kuchtey et al., 2006</xref>). In addition, it has been suggested that type I IFN may improve the immunogenicity of BCG vaccination against <italic>M. tuberculosis</italic> infection in mouse and guinea pig models (<xref rid="bib14" ref-type="bibr">Bottai et al., 2015</xref>; <xref rid="bib56" ref-type="bibr">Gr&#x000f6;schel et al., 2017</xref>; <xref rid="bib101" ref-type="bibr">Rivas-Santiago and Guerrero, 2017</xref>). Recombinant expression of the ESX-1 protein secretion system in the attenuated BCG vaccine has been shown to increase the protective effect of vaccination against <italic>M. tuberculosis</italic> infection (<xref rid="bib14" ref-type="bibr">Bottai et al., 2015</xref>; <xref rid="bib56" ref-type="bibr">Gr&#x000f6;schel et al., 2017</xref>). This increased protection correlated with enhanced IFN-&#x003b2; production by macrophages infected with recombinant ESX-1&#x02013;expressing BCG (<xref rid="bib56" ref-type="bibr">Gr&#x000f6;schel et al., 2017</xref>). However, the contribution of type I IFN in the protection conferred by ESX-1&#x02013;expressing BCG vaccine still requires investigation. In support for a role of type I IFN in increasing BCG vaccine efficacy, an independent study has shown that administration of IFN-&#x003b1; during BCG vaccination promotes the production of host-protective cytokines (e.g., IFN-&#x003b3;, TNF-&#x003b1;, and IL-12) and confers increased protection against <italic>M. tuberculosis</italic> infection over that observed with BCG alone (<xref rid="bib101" ref-type="bibr">Rivas-Santiago and Guerrero, 2017</xref>). These findings suggest that type I IFN may play a friendly protective role in the context of BCG-induced immunity and could be targeted to improve preventive vaccination against tuberculosis.</p><p>In vitro experiments in human peripheral blood cells have shown that treatment with type I IFN can increase DC maturation and IL-12 production following BCG infection, which then promotes T cell priming and production of IFN-&#x003b3; (<xref rid="bib52" ref-type="bibr">Giacomini et al., 2009</xref>), and may help to explain the positive effects of type I IFN during vaccination. Whereas addition of IFN-&#x003b2; at the time of infection has been shown to negatively affect proinflammatory cytokine production via IL-10&#x02013;dependent and &#x02013;independent mechanisms (<xref rid="bib81" ref-type="bibr">Mayer-Barber et al., 2011</xref>; <xref rid="bib84" ref-type="bibr">McNab et al., 2014</xref>), basal type I IFN signaling has been shown to be required for maximal production of IL-12 and TNF-&#x003b1; by macrophages in response to <italic>M. tuberculosis</italic> infection (<xref rid="bib84" ref-type="bibr">McNab et al., 2014</xref>). Indeed, <italic>Ifnar1</italic><sup>&#x02212;/&#x02212;</sup> macrophages have been shown to produce lower levels of IL-12 and TNF-&#x003b1; in response to <italic>M. tuberculosis</italic> infection compared with WT macrophages (<xref rid="bib84" ref-type="bibr">McNab et al., 2014</xref>). Tonic type I IFN signaling has also been reported to be important for optimal IL-12 production by macrophages (<xref rid="bib59" ref-type="bibr">Howes et al., 2016</xref>) and DCs (<xref rid="bib50" ref-type="bibr">Gautier et al., 2005</xref>) in other contexts. Moreover, pretreatment of WT macrophages with IFN-&#x003b2; for &#x0003e;8 h before <italic>M. tuberculosis</italic> infection enhanced the production of IL-12 and TNF-&#x003b1; (<xref rid="bib84" ref-type="bibr">McNab et al., 2014</xref>), indicating that the timing of type I IFN signaling may be important in determining the effects of type I IFN during <italic>M. tuberculosis</italic> infection. Thus, these findings suggest that early tonic type I IFN signaling can elicit friendly functions during <italic>M. tuberculosis</italic> infection by priming innate immune cells for the production of proinflammatory host-protective cytokines (<xref ref-type="fig" rid="fig2">Fig. 2</xref>).</p></sec><sec disp-level="2" id="s09"><title>Closing remarks</title><p>Members of the type I IFN family were first discovered for their ability to interfere with viral replication and are well known for their antiviral responses (<xref rid="bib124" ref-type="bibr">Yan and Chen, 2012</xref>; <xref rid="bib25" ref-type="bibr">Crouse et al., 2015</xref>). Unlike their largely protective role in viral infections, this family of cytokines plays a less predictable role in bacterial infection (<xref rid="bib117" ref-type="bibr">Trinchieri, 2010</xref>; <xref rid="bib85" ref-type="bibr">McNab et al., 2015</xref>; <xref rid="bib114" ref-type="bibr">Stifter and Feng, 2015</xref>; <xref rid="bib79" ref-type="bibr">Mayer-Barber and Yan, 2017</xref>). Over the past decade, numerous studies have uncovered a foe-like pathogenic role of type I IFN in tuberculosis. Patients with active tuberculosis have a blood transcriptional gene signature dominated by type I IFN&#x02013;related genes that is correlated with disease severity and is down-regulated following successful treatment (<xref ref-type="table" rid="tbl1">Table 1</xref>). In experimental models, elevated levels of type I IFN are associated with the virulence of <italic>M. tuberculosis</italic> strains and increased host susceptibility. Several mechanisms underlying the pathogenic role of type I IFN in tuberculosis have been described, including induction of IL-10 and negative regulation of the IL-12/IFN-&#x003b3; and IL-1&#x003b2;/PGE2 host-protective responses. However, there is also evidence that type I IFN may play a friendly role in certain contexts, highlighting the complex role of type I IFN in tuberculosis (<xref ref-type="fig" rid="fig2">Fig. 2</xref>). Although high levels of type I IFN have negative effects during the course of <italic>M. tuberculosis</italic> infection, tonic I IFN signaling or low levels of type I IFN in the context of low mycobacterial loads may in turn have positive effects by priming host-protective responses. This may explain the protective effects of IFN-&#x003b1; therapy together with anti-mycobacterial drugs in patients with active disease. Thus, it is likely that a balanced induction of this family of cytokines is required for optimal protection. Various signaling pathways have been described to induce type I IFN production in response to <italic>M. tuberculosis</italic> infection (<xref ref-type="fig" rid="fig1">Fig. 1</xref>). Differential activation of these pathways and/or high or low engagement of these signaling pathways during infection may contribute to the induction of distinct levels of type I IFN and the differential virulence of <italic>M. tuberculosis</italic> strains. In addition, potential differences in temporal and spatial induction of individual IFN-&#x003b1; subtypes and IFN-&#x003b2; during infection could contribute to variations in disease outcome and determine foe or friend features of the type I IFN response. A further unexplored area is the possible differential role of IFNAR subunits (IFNAR1 and IFNAR2) in determining the outcome of type I IFN signaling. Dominant IFNAR1 expression has been shown to favor IFN-&#x003b2; ligation and activation of the protein kinase B (also known as Akt) pathway over the classical JAK&#x02013;STAT pathway (<xref rid="bib35" ref-type="bibr">de Weerd et al., 2013</xref>). Therefore, differential expression of IFNAR subunits on the relevant responding cells during <italic>M. tuberculosis</italic> infection could be another factor regulating detrimental versus protective activities of type I IFN signaling during infection. Deciphering the mechanisms underlying the differential induction of type I IFN and what determines the outcome of type I IFN signaling during <italic>M. tuberculosis</italic> infection, from induction of IL-10 to the regulation of the IL-12/IFN-&#x003b3; and IL-1&#x003b2;/PGE2 host-protective responses, may offer new avenues for host-directed therapies for tuberculosis. In addition, such research may yield important basic information about type I IFN induction and function that will enhance our broader understanding of how this major cytokine family impacts on disease outcomes.</p></sec>